Pliant Therapeutics, Inc. (PLRX)

Market Cap	90.02M
Revenue (ttm)	n/a
Net Income (ttm)	-210.30M
Shares Out	61.24M
EPS (ttm)	-3.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	806,560
Open	1.500
Previous Close	1.510
Day's Range	1.460 - 1.560
52-Week Range	1.260 - 16.520
Beta	1.19
Analysts	Hold
Price Target	9.79 (+565.99%)
Earnings Date	Mar 3, 2025

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 171
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX
• Website: https://pliantrx.com

Analyst Forecast

According to 10 analysts, the average rating for PLRX stock is "Hold." The 12-month stock price forecast is $9.79, which is an increase of 565.99% from the latest price.

Price Target

$9.79

(565.99% upside)

Analyst Consensus: Hold